Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy

A possible tumor marker

Feng Ming Kong, Mary Kay Washington, Randy L. Jirtle, Mitchell S. Anscher

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Purpose: To determine the frequency with which elevated plasma transforming growth factor-β1 (TGFβ1) concentrations occur in lung cancer patients, to determine the kinetics of TGFβ1 expression during and after radiotherapy and to correlate plasma TGFβ1 levels with disease status after treatment. Materials and methods: Plasma samples were obtained before, during and after radiotherapy in 54 patients with lung cancer and 20 normal controls. Plasma TGFβ1 levels were measured using an enzyme-linked immunosorbent assay. Results: Baseline TGFβ1 levels in lung cancer patients and normal controls were 13.0 ± 2.5 and 4.4 ± 0.3 ng/ml, respectively. Elevated TGFβ1 were found in 50% (27/54) of lung cancer patients. During radiation therapy plasma TGFβ1 levels declined, however, by the completion of treatment the mean TGFβ1 level had not normalized in patients with lung cancer. The TGFβ1 level at last follow-up correlated with disease status in those patients with an increased pretreatment plasma level. Three of four patients with no evidence of cancer had normal follow-up TGFβ1 levels, compared to 2/16 patients with residual or recurrent tumor (P = 0.02). Conclusions: Elevated plasma TGFβ1 levels occur frequently in patients with lung cancer. In those patients with an elevated plasma TGFβ1 level at diagnosis, monitoring this level may be useful in detecting both disease persistence and recurrence after therapy.

Original languageEnglish (US)
Pages (from-to)47-59
Number of pages13
JournalLung Cancer
Volume16
Issue number1
DOIs
StatePublished - Dec 1 1996

Fingerprint

Transforming Growth Factors
Tumor Biomarkers
Lung Neoplasms
Radiotherapy
Neoplasms
Therapeutics
Enzyme-Linked Immunosorbent Assay

Keywords

  • lung cancer
  • radiotherapy
  • transforming growth factor β1 (TGFβ1)
  • tumor marker

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy : A possible tumor marker. / Kong, Feng Ming; Washington, Mary Kay; Jirtle, Randy L.; Anscher, Mitchell S.

In: Lung Cancer, Vol. 16, No. 1, 01.12.1996, p. 47-59.

Research output: Contribution to journalArticle

Kong, Feng Ming ; Washington, Mary Kay ; Jirtle, Randy L. ; Anscher, Mitchell S. / Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy : A possible tumor marker. In: Lung Cancer. 1996 ; Vol. 16, No. 1. pp. 47-59.
@article{dec1d412043c453185fafdb158001c2a,
title = "Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker",
abstract = "Purpose: To determine the frequency with which elevated plasma transforming growth factor-β1 (TGFβ1) concentrations occur in lung cancer patients, to determine the kinetics of TGFβ1 expression during and after radiotherapy and to correlate plasma TGFβ1 levels with disease status after treatment. Materials and methods: Plasma samples were obtained before, during and after radiotherapy in 54 patients with lung cancer and 20 normal controls. Plasma TGFβ1 levels were measured using an enzyme-linked immunosorbent assay. Results: Baseline TGFβ1 levels in lung cancer patients and normal controls were 13.0 ± 2.5 and 4.4 ± 0.3 ng/ml, respectively. Elevated TGFβ1 were found in 50{\%} (27/54) of lung cancer patients. During radiation therapy plasma TGFβ1 levels declined, however, by the completion of treatment the mean TGFβ1 level had not normalized in patients with lung cancer. The TGFβ1 level at last follow-up correlated with disease status in those patients with an increased pretreatment plasma level. Three of four patients with no evidence of cancer had normal follow-up TGFβ1 levels, compared to 2/16 patients with residual or recurrent tumor (P = 0.02). Conclusions: Elevated plasma TGFβ1 levels occur frequently in patients with lung cancer. In those patients with an elevated plasma TGFβ1 level at diagnosis, monitoring this level may be useful in detecting both disease persistence and recurrence after therapy.",
keywords = "lung cancer, radiotherapy, transforming growth factor β1 (TGFβ1), tumor marker",
author = "Kong, {Feng Ming} and Washington, {Mary Kay} and Jirtle, {Randy L.} and Anscher, {Mitchell S.}",
year = "1996",
month = "12",
day = "1",
doi = "10.1016/S0169-5002(96)00611-3",
language = "English (US)",
volume = "16",
pages = "47--59",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy

T2 - A possible tumor marker

AU - Kong, Feng Ming

AU - Washington, Mary Kay

AU - Jirtle, Randy L.

AU - Anscher, Mitchell S.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Purpose: To determine the frequency with which elevated plasma transforming growth factor-β1 (TGFβ1) concentrations occur in lung cancer patients, to determine the kinetics of TGFβ1 expression during and after radiotherapy and to correlate plasma TGFβ1 levels with disease status after treatment. Materials and methods: Plasma samples were obtained before, during and after radiotherapy in 54 patients with lung cancer and 20 normal controls. Plasma TGFβ1 levels were measured using an enzyme-linked immunosorbent assay. Results: Baseline TGFβ1 levels in lung cancer patients and normal controls were 13.0 ± 2.5 and 4.4 ± 0.3 ng/ml, respectively. Elevated TGFβ1 were found in 50% (27/54) of lung cancer patients. During radiation therapy plasma TGFβ1 levels declined, however, by the completion of treatment the mean TGFβ1 level had not normalized in patients with lung cancer. The TGFβ1 level at last follow-up correlated with disease status in those patients with an increased pretreatment plasma level. Three of four patients with no evidence of cancer had normal follow-up TGFβ1 levels, compared to 2/16 patients with residual or recurrent tumor (P = 0.02). Conclusions: Elevated plasma TGFβ1 levels occur frequently in patients with lung cancer. In those patients with an elevated plasma TGFβ1 level at diagnosis, monitoring this level may be useful in detecting both disease persistence and recurrence after therapy.

AB - Purpose: To determine the frequency with which elevated plasma transforming growth factor-β1 (TGFβ1) concentrations occur in lung cancer patients, to determine the kinetics of TGFβ1 expression during and after radiotherapy and to correlate plasma TGFβ1 levels with disease status after treatment. Materials and methods: Plasma samples were obtained before, during and after radiotherapy in 54 patients with lung cancer and 20 normal controls. Plasma TGFβ1 levels were measured using an enzyme-linked immunosorbent assay. Results: Baseline TGFβ1 levels in lung cancer patients and normal controls were 13.0 ± 2.5 and 4.4 ± 0.3 ng/ml, respectively. Elevated TGFβ1 were found in 50% (27/54) of lung cancer patients. During radiation therapy plasma TGFβ1 levels declined, however, by the completion of treatment the mean TGFβ1 level had not normalized in patients with lung cancer. The TGFβ1 level at last follow-up correlated with disease status in those patients with an increased pretreatment plasma level. Three of four patients with no evidence of cancer had normal follow-up TGFβ1 levels, compared to 2/16 patients with residual or recurrent tumor (P = 0.02). Conclusions: Elevated plasma TGFβ1 levels occur frequently in patients with lung cancer. In those patients with an elevated plasma TGFβ1 level at diagnosis, monitoring this level may be useful in detecting both disease persistence and recurrence after therapy.

KW - lung cancer

KW - radiotherapy

KW - transforming growth factor β1 (TGFβ1)

KW - tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0031040409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031040409&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(96)00611-3

DO - 10.1016/S0169-5002(96)00611-3

M3 - Article

VL - 16

SP - 47

EP - 59

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -